非侵入性產前檢測 (NIPT) 市場：按產品/服務、應用、技術、時間段、最終用戶和地區分類。

預計到2026年，非侵入性產前檢測（NIPT）市場規模將達到56.2億美元，到2033年將達到113.7億美元。預計從2026年到2033年，該市場將以10.6%的複合年成長率成長。

全球非侵入性產前檢測 (NIPT) 市場利用非侵入性產前檢測 (NIPT) 技術篩檢母體血液中的胎兒 DNA，以確定胎兒是否有遺傳異常的高風險，且無需對懷孕或胎兒造成任何侵入性操作。這些檢測分析母體血液中循環的胎盤來源的遊離細胞 DNA (cfDNA)。它們可以檢測唐氏症、13 三體症、18 三體症、性染色體異常和其他異常等遺傳疾病的風險。隨著基因組技術的進步，NIPT 已成為產前篩檢的先驅技術之一，並因其能夠提供準確的結果且避免了羊膜穿刺等侵入性檢查帶來的流產風險，而受到全球孕婦的廣泛歡迎。

市場動態

全球非侵入性產前檢測 (NIPT) 市場的發展受到多種因素的推動，包括孕婦年齡成長、唐氏症出生率上升、NIPT 認知度提高以及診斷工具的技術進步。然而，低收入國家診斷服務取得管道有限以及與墮胎相關的倫理問題限制市場成長。開發中國家尚未開發的市場以及正在進行的研發工作，為拓展 NIPT 在基因突變、染色體微缺失和微重複檢測方面的應用範圍提供了巨大的機會。

本次調查的主要特點

• 本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
• 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
• 本研究根據以下參數創建了全球無創產前檢測 (NIPT) 市場主要公司的概況：公司亮點、產品系列、關鍵亮點、財務績效和策略。
• 透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
• 這份全球無創產前檢測 (NIPT) 市場報告的目標受群眾外包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等行業利益相關相關人員。
• 透過分析全球無創產前檢測 (NIPT) 市場中使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
  • 抑制因子
  • 機會
• 影響分析
• 主要進展
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特的分析
• 併購情景
• 產業趨勢

第4章 全球非侵入性產前檢測（NIPT）市場：依產品/服務分類，2021-2033年

• 產品
• 服務

第5章 全球非侵入性產前檢測（NIPT）市場：依應用領域分類，2021-2033年

• 三體檢測
• 微缺失的檢測
• 性染色體非整倍體的檢測

第6章 全球非侵入性產前檢測（NIPT）市場：依技術分類，2021-2033年

• 次世代定序（NGS）
• 聚合酵素鏈鎖反應（PCR）
• 陣列技術
• 滾動循環放大

第7章 全球非侵入性產前檢測（NIPT）市場：依時期分類，2021-2033年

• 懷孕0-12週
• 懷孕13-24週
• 懷孕25-36週

第8章 全球非侵入性產前檢測（NIPT）市場：依最終用戶分類，2021-2033年

• 醫院
• 診斷檢查室
• 居家醫療
• 其他

第9章 全球非侵入性產前檢測（NIPT）市場：按地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲國家
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 中東
  • 海灣合作理事會國家
  • 以色列
  • 其他中東國家
• 非洲
  • 南非
  • 北非
  • 中非

第10章 競爭格局

• Illumina, Inc.
• Natera, Inc.
• Roche Diagnostics
• Ariosa Diagnostics
• Verinata Health, Inc.
• Yourgene Health
• Centogene NV
• Eurofins Scientific
• Hoffmann-La Roche Ltd.
• LabCorp
• Quest Diagnostics
• BGI Genomics
• MedGenome Labs
• Genetic Technologies Limited
• Myriad Genetics, Inc.

第11章 分析師建議

• 機會分析
• 分析師意見
• Coherent Opportunity Map

第12章 參考文獻與調查方法

• 參考
• 調查方法
• 關於本公司

Non-Invasive Prenatal Testing (NIPT) Market is estimated to be valued at USD 5.62 Bn in 2026 and is expected to reach USD 11.37 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.6% from 2026 to 2033.

Global Non invasive Prenatal Testing (NIPT) Market is used to screen fetal DNA in the mother's bloodstream to check if the fetus is at a high risk of genetic abnormalities without being invasive to the pregnancy or the fetus. These tests analyze cell free DNA (cfDNA) from the placenta that circulates in the mother's bloodstream. They can check the risk of genetic conditions like Down's syndrome, Trisomy 13, Trisomy 18, sex chromosome aneuploidies, and other abnormalities. With advancements in genomic technologies, NIPT has become one of the pioneering techniques used for prenatal screening and is gaining immense popularity among expectant mothers worldwide as it provides accurate results and avoids risks of miscarriage associated with invasive tests like amniocentesis.

Market Dynamics

The global Non invasive Prenatal Testing (NIPT) market is driven by factors such as increasing maternal age, rising incidence of babies born with Down's syndrome, growing awareness about NIPT, and technological advancements in diagnostic tools. However, limited access to diagnostic services in low income countries and ethical issues related to abortion restrain market growth. Significant opportunities include untapped markets in developing countries and ongoing R&D to expand applications of NIPT to detect genetic mutations and chromosomal microdeletion or duplications.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global Non invasive Prenatal Testing (NIPT) market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Illumina, Inc., Natera, Inc., Roche Diagnostics, Ariosa Diagnostics, Verinata Health, Inc., Yourgene Health, Centogene N.V., Eurofins Scientific, F. Hoffmann La Roche Ltd., LabCorp, Quest Diagnostics, BGI Genomics, MedGenome Labs, Genetic Technologies Limited, and Myriad Genetics, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up gradation, market expansion, and marketing tactics.
• The global Non invasive Prenatal Testing (NIPT) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global Non invasive Prenatal Testing (NIPT) market.

Market Segmentation

• By Product & Service Insights (Revenue, USD Bn, 2021 - 2033)
• Product
  • Consumables
  • Assay Kits and Reagents
  • Instruments
• Services
• By Application Insights (Revenue, USD Bn, 2021 - 2033)
• Trisomy Detection
• Microdeletion Detection
• Sex Chromosome Aneuploidy Detection
• By Technology Insights (Revenue, USD Bn, 2021 - 2033)
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Array Technology
• Rolling Circular Amplification
• By Period Insights (Revenue, USD Bn, 2021 - 2033)
• 0-12 Weeks
• 13-24 Weeks
• 25-36 Weeks
• By End User Insights (Revenue, USD Bn, 2021 - 2033)
• Hospitals
• Diagnostic Laboratories
• Home Care Settings
• Others
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
• Illumina, Inc.
• Natera, Inc.
• Roche Diagnostics
• Ariosa Diagnostics
• Verinata Health, Inc.
• Yourgene Health
• Centogene N.V.
• Eurofins Scientific
• Hoffmann-La Roche Ltd.
• LabCorp
• Quest Diagnostics
• BGI Genomics
• MedGenome Labs
• Genetic Technologies Limited
• Myriad Genetics, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Non-invasive Prenatal Testing (NIPT) Market, By Product & Service
  • Global Non-invasive Prenatal Testing (NIPT) Market, By Application
  • Global Non-invasive Prenatal Testing (NIPT) Market, By Technology
  • Global Non-invasive Prenatal Testing (NIPT) Market, By Period
  • Global Non-invasive Prenatal Testing (NIPT) Market, By End User
  • Global Non-invasive Prenatal Testing (NIPT) Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Driver
  • Restraint
  • Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Non-invasive Prenatal Testing (NIPT) Market, By Product & Service, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Product
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
    • Consumables
    • Assay Kits and Reagents
    • Instruments
• Services
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Non-invasive Prenatal Testing (NIPT) Market, By Application, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Trisomy Detection
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Microdeletion Detection
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Sex Chromosome Aneuploidy Detection
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Non-invasive Prenatal Testing (NIPT) Market, By Technology, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Next-Generation Sequencing (NGS)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Polymerase Chain Reaction (PCR)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Array Technology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Rolling Circular Amplification
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Non-invasive Prenatal Testing (NIPT) Market, By Period, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• 0-12 Weeks
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• 13-24 Weeks
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• 25-36 Weeks
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Global Non-invasive Prenatal Testing (NIPT) Market, By End User, 2021 - 2033, (USD Bn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2021 - 2033
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Diagnostic Laboratories
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Home Care Settings
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Global Non-invasive Prenatal Testing (NIPT) Market, By Region, 2021 - 2033, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2026,2028 & 2033, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Product & Service, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Period, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Product & Service, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Period, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Product & Service, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Period , 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Product & Service, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Period , 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Product & Service, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Period , 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Product & Service, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Period, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• Illumina, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Natera, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Roche Diagnostics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Ariosa Diagnostics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Verinata Health, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Yourgene Health
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Centogene N.V.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eurofins Scientific
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hoffmann-La Roche Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• LabCorp
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Quest Diagnostics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BGI Genomics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• MedGenome Labs
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Genetic Technologies Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Myriad Genetics, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us